CytomX Therapeutics, Inc. Board of Directors

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Mr. Lloyd A. Rowland Jr., J.D.

Mr. Lloyd A. Rowland Jr., J.D.

Senior VP, General Counsel, Chief Compliance Officer & Secretary

Ms. Danielle Olander-Moghadassian

Ms. Danielle Olander-Moghadassian

Senior VP & Chief Human Resources Officer

Mr. Jeffrey Landau B.S., M.B.A.

Mr. Jeffrey Landau B.S., M.B.A.

Senior VP, Head of Strategy & Chief Business Officer

Ms. Leslie Robbins

Ms. Leslie Robbins

Senior Vice President of Intellectual Property

Dr. Marcia P. Belvin Ph.D.

Dr. Marcia P. Belvin Ph.D.

Senior VP & Chief Scientific Officer

Ms. Dawn Benson

Ms. Dawn Benson

Senior Vice President of Quality & Product Manufacturing

Mr. Christopher W. Ogden

Mr. Christopher W. Ogden

Chief Financial Officer

Dr. Hoyoung Huh M.D., Ph.D.

Dr. Hoyoung Huh M.D., Ph.D.

Special Advisor to Chief Executive Officer

Dr. Yu-Waye Chu M.D.

Dr. Yu-Waye Chu M.D.

Chief Medical Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.